Skip to main content
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2012 Jun 14;518(1):19–22. doi: 10.1016/j.neulet.2012.04.033

Study of the genetic variability in a Parkinson's Disease gene: EIF4G1

Arianna Tucci a,, Gavin Charlesworth a, Una-Marie Sheerin a, Vincent Plagnol b, Nicholas W Wood a, John Hardy a
PMCID: PMC3769807  PMID: 22561553

Highlights

► Mutations in the EIF4G1 gene have been found in patients with Parkinson's Disease (PD) [2]. ► We investigate the mutations in a familial PD cohort and in sub-Saharian Africans and Europeans. ► We failed to identify any mutation in the PD cohort. We identify the p.A502V (previously associated to PD) in Caucasians. ► Mutations in the EIF4G1 gene are a very rare cause of PD in European individuals. ► The protein can tolerate some extent of genetic variability.

Keywords: Parkinson's Disease, EIF4G1

Abstract

Chartier-Harlin and colleagues [2] recently reported mutations in the eukaryotic translation initiation factor 4-gamma (EIF4G1) gene in families with parkinsonism. Large-scale screening found two mutations (p.R1205H and p.A502V) only in affected individuals, although their relative frequency was very low. The aim of this study was to investigate EIF4G1 parkinsonism-related variants in two separate cohorts and study coding variability across the gene. We first screened a series of familial Parkinson's Disease (PD) patients in an attempt to confirm previous results by showing segregation. Then, to determine the extent of coding variation in the gene, we first screened a cohort of sub-Saharan African individuals from the Centre d’Etude du Polymorphisme Humain – Human Genome Diversity Cell Line Panel (HGDP) [1] and then analyzed data from 5350 individuals National Heart, Lung, and Blood Institute (NHLBI) exome sequencing project. We failed to identify any PD-related mutations in the familial samples. Conversely we found the p.A502V variant in the NHLBI population. We observed a high number of coding polymorphism in the exons where the two PD variants have been previously reported. We conclude that either EIF4G1 variants are an extremely rare cause of familial PD in Caucasian cohorts, or that A502V is in fact a rare benign variant not involved in PD aetiology. Our data also suggests that the protein can tolerate some extent of variability particularly at this point of the gene.


Recently, a new gene (EIF4G1) has been identified in one family with autosomal dominant late-onset Parkinson's Disease [2]. Linkage was ascribed to a region at chromosome 3q26–28 containing approximately 159 genes. Sequence analysis found only one novel coding variant (p.R1205H in the EIF4G1 gene) which segregated with disease, which was absent in 4050 controls and which was evolutionary conserved in mammals. Screening a cohort of about 4800 PD cases (familial and sporadic) identified nine additional patients of the p.R1205H mutation. Further molecular analysis of the EIF4G1 gene in a large case–control cohort (4500 cases and 3800 controls) identified another novel missense mutation (p.A502V) in three PD individuals, which was not found in controls. These data indicate that these variants are extremely rare in the PD population (0.2% for p.R1205H and 0.06% for p.A502V). Assignment of pathogenicity can be difficult when variants are very rare. With this background, we screened 150 familial PD cases from our UK familial Parkinson's Disease series, in which we have previously identified LRRK2, VPS35 and SNCA mutations [5,7] in order to determine whether we could provide further that this gene is indeed a PD-related locus. We also assessed these coding positions in a set of African samples (Table 1) from the Human Diversity series – a standard panel of African samples [1], as African samples have the greatest diversity and offer a rapid route to the identification of benign polymorphisms [4]. Briefly, exon 8 and exon 22 of the EIF4G1 gene (NM_182917.3) were PCR amplified and sequenced in the two cohorts for a total of 114 African samples and 150 familial PD cases.

Table 1.

Number of African samples studied per population and geographic regions.

No. of samples Population Geographic origin
35 Biaka Pygmy Central African Republic
15 Mbuti Pygmy Democratic Republic of Congo
12 Bantu N.E. Kenya
7 San Namibia
26 Yoruba Nigeria
24 Mandenka Senegal
8 Bantu S.E. Pedi South Africa

To obtain a more exhaustive description of the pattern of variability in that gene we also extracted genotype data from the NHLBI exome sequencing project (Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA (http://evs.gs.washington.edu/EVS/) [January 2011], which includes exome data for 3500 American individuals of European descent and 1850 African American. Frequencies were computed using VCFtools. We used the software ANNOVAR [8] to annotate the function of the variants.

We failed to identify any mutation previously reported to be associated with PD our familial cohort, but we identified one coding change (P486S) in two PD individuals. The P486S variant is reported in dbSNP (rs112545306). Interestingly it has been observed in African-Americans (http://snp.gs.washington.edu/EVS), with a frequency of 0.15%.

We identified six non-synonymous changes in exon 8 and in exon 22 in the African individuals. Of these, one is a novel change (P382L), the others are variants recently reported in dbSNP and found mainly in African populations (http://snp.gs.washington.edu/EVS). To predict the impact on protein function of these non-synonymous variants, we performed an in silico analysis using the software PolyPhen and SIFT [6] and all were predicted to be benign (Table 2).

Table 2.

EIF4G1 coding variant detected in the African cohort (NM_182917.4).

Nucleotide change Protein change SNP accession number Frequency Population Effect (SIFT)
c.870G>A M290I rs144947145 0.01 San, Bantu SE Tolerated
c.913C>T R305C rs116508885 0.01 Youruba Tolerated
c.932A>G Y311C rs16858632 0.03 Bantu SW, Bantu NE, Yoruba, Mandenka Tolerated
c.1145C>T P382L NA 0.004 San Tolerated
c.1429G>A E477K rs145228718 0.004 Mandenka Tolerated
c.3918G>A R1216H rs34086109 0.004 Biaka Pygmy Tolerated

Analysis of the NHLBI samples allowed us to detect the A502V variant in two European-American individuals (frequency of 0.02%). We identified 95 nonsynonymous SNP over 32 exons in total (NM_182917.3). Of note, 36 of them are located in exon 8 and exon 22 (Table 3). To investigate coding variability across the EIF4G1 gene we extracted the data from the NHLBI dataset and computed the average number of pairwise amino acid differences between two randomly selected European-American haplotypes from the NHLBI dataset (Methods). On average two such EIF4G1 sequences diverge by 0.45 aminoacids. 82% of this variability (0.37 amino-acid differences) locates to exon 8, where the A502V lies. 9.8% of this variability locates to exon 22 (0.098 amino-acid differences). Combined with the identification of six coding variants in exons 8 and 22 in African samples, these data are consistent with a more limited selective pressure and a higher sequence variability in this region of the EIF4G1 protein.

Table 3.

EIF4G1 coding variants present in NHLBI Exome Sequencing Project (NM_182917.4). EA = European American population. AA = African American population.

Nucleotide change Protein change SNP accession number Frequency (EA) Frequency (AA) Exon
c.C71T P24L 0.000142 0 2
c.C167G A56G 0.000142 0 3
c.C211T P71S rs113810947 0.000285 0 3
c.282C>G I94M 0 0.000268 3
c.451C>G V151L 0.000143 0 5
c.481A>G A161T rs13319149 0.996722 0.999465 5
C.602G>A R201H rs34838305 0.000427 0 6
C.608C>T A203V 0.000142 0 6
C.704G>A R235Q rs144543953 0.000142 0.000268 8
C.731G>A R244Q rs147855566 0.000142 0 8
C.779C>T S260L 0.000142 0 8
c.821C>T P274L rs139626338 0 0.000268 8
c.870G>A M290I rs144947145 0 0.001338 8
c.913C>T R305C rs116508885 0 0.00321 8
c.914G>A R205H rs151151194 0.000142 0.000268 8
c.926A>G E309G 0.000142 0 8
c.932A>G Y311C rs16858632 0.000427 0.059658 8
c.1001A>C P334Q 0.000285 0 8
c.1013C>T S338F rs139021806 0 0.000268 8
c.1036C>A Q346K 0 0.000268 8
c.1054G>T A352S 0.000142 0 8
c.1063A>G T355A 0 0.000268 8
c.1064C>T T355I 0 0.000268 8
c.1142C>G A381G rs142095694 0.000142 0 8
c.1256G>T S419I rs138207269 0 0.000535 8
c.1294A>G M432V rs2178403 0.759544 0.943553 8
c.1298C>T A433V rs145998921 0.000142 0 8
c.1309A>G I437V rs144222028 0 0.000268 8
c.1316C>A S439Y rs148709174 0.000142 0 8
c.1331C>T T444M rs143014570 0 0.000268 8
c.1352C>A P451Q rs147419996 0.000142 0 8
c.1429G>A E477K rs145228718 0 0.000268 8
c.1456C>T P486S rs112545306 0.00057 0.000803 8
c.1505C>T A502V rs111290936 0.000285 0 8
c.1610C>T A537V 0 0.000268 10
c.1648G>C A550P rs111924994 0.001994 0.000535 10
c.1679G>A G560D rs149685875 0.000142 0 10
c.1696C>T R566C rs145521479 0.000142 0.000268 10
c.1700C>A P567H rs140212150 0 0.000268 10
c.1754A>C E585A 0 0.000268 10
c.1801T>C W601R rs145247318 0 0.000268 11
c.1831C>T R611C 0 0.000268 11
c.1980A>G I660M 0.000142 0 12
c.1982A>G N661S rs145780534 0.000142 0 12
c.2096G>C G699A 0.000142 0 13
c.2114C>G S705C rs141054452 0.000142 0 13
c.2152G>C A718P rs111396765 0.001567 0.000268 13
c.2225C>T T742M rs147678593 0 0.004013 13
c.2276A>G Q759R 0.000142 0 14
c.2278G>C D760H rs142947014 0.000142 0 14
c.2386A>G K796E 0 0.000268 14
c.2419A>G I807V rs62287499 0.000427 0 14
c.2488A>T T830S rs111500185 0.000285 0 15
c.2612A>C E871A 0.000142 0 15
c.2671A>G I891V 0 0.000268 16
c.2882A>G N961S rs191888688 0 0.000268 17
c.3187C>T R1063C 0.000142 0 19
c.3221C>T T1074I rs146433145 0.000142 0 19
c.3343C>T R1115C rs150054202 0 0.000268 21
c.3428A>G Q1143R rs145414660 0 0.000268 21
c.3482G>A R1161H rs139135683 0.000427 0 22
c.3511C>T R1171C rs141684202 0 0.000268 22
c.3529C>T R1177C 0 0.000268 22
c.3580C>T R1194W 0.000142 0 22
c.3584G>A S1195N 0.000142 0 22
c.3592C>T R1198W rs113388242 0 0.000268 22
c.3617G>A R1206H rs112176450 0.000285 0 22
c.3649C>T R1207C 0.000143 0 22
c.3650G>A R1217H rs34086109 0 0.010433 22
c.3652G>A G1217R rs138270117 0 0.000268 22
c.3686C>T P1299L 0 0.000268 23
c.3688C>G P1230A rs35629949 0.005842 0.001606 23
c.3701T>C L1234P rs2230570 0.021937 0.080257 23
c.3743A>G K1248R 0.000142 0 23
c.3773A>G N1258S rs73053766 0 0.001873 23
c.3935C>T S1312F 0 0.000268 24
c.3937A>G T1313A rs144570332 0.000142 0.000803 24
c.3988A>G M1330V rs112809828 0.000285 0 25
c.4067T>C M1356T rs144059151 0.000855 0 25
c.4068G>C M1356I rs145975905 0.000285 0 25
c.4081A>G R1361G rs139793721 0 0.000268 25
c.4106C>T P1369L rs142064428 0 0.000803 26
c.4184C>T T1395M rs112441721 0 0.000268 27
c.4201G>A G1401R rs149821418 0.000142 0.000803 27
c.4229A>C E1410A rs141776790 0 0.000268 27
c.4259A>G E1420G 0 0.000268 27
c.4292C>T S1431L 0.000142 0.000268 28
c.4300C>T P1434S rs147696097 0.000142 0 28
c.4379G>A R1460Q 0.000142 0 28
c.4399G>A A1467T rs148270724 0.000142 0 29
c.4433C>T T1478M rs141379472 0.000142 0 29
c.4454C>T T1485M 0.000142 0 29
c.4486A>T T1496S 0 0.000268 29
c.4712C>T A1571V rs144462594 0.000142 0 31
c.4772G>A R1591H 0.000142 0 31

These data, combined with the presence of the A502V in the NHLBI population with 0.02% frequency and our failure to identify any PD mutation carrier in our familial cohort, are consistent with the interpretation that either EIF4G1 variants are an extremely rare cause of familial PD in Caucasian cohorts, or that A502V is in fact a rare benign variant not involved in PD aetiology.

Role of the funding source

This study was supported by Parkinson's Disease Society (AT) and by the Medical Research Council and Wellcome Trust Disease Centre (grant WT089698/Z/09/Z). DNA extraction work was undertaken at University College London Hospitals, University College London, who received a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centres funding.

Disclosure statement

Arianna Tucci, Gavin Charlesworth, Una-Marie Sheerin, Vincent Plagnol, Nick Wood, John Hardy report no disclosures.

Acknowledgements

We thank all patients and all families who supported the donation of tissue for research.

References

  • 1.Cann H.M., de Toma C., Cazes L., Legrand M.F., Morel V., Piouffre L., Bodmer J., Bodmer W.F., Bonne-Tamir B., Cambon-Thomsen A., Chen Z., Chu J., Carcassi C., Contu L., Du R., Excoffier L., Ferrara G.B., Friedlaender J.S., Groot H., Gurwitz D., Jenkins T., Herrera R.J., Huang X., Kidd J., Kidd K.K., Langaney A., Lin A.A., Mehdi S.Q., Parham P., Piazza A., Pistillo M.P., Qian Y., Shu Q., Xu J., Zhu S., Weber J.L., Greely H.T., Feldman M.W., Thomas G., Dausset J., Cavalli-Sforza L.L. A human genome diversity cell line panel. Science. 2002;296:261–262. doi: 10.1126/science.296.5566.261b. [DOI] [PubMed] [Google Scholar]
  • 2.Chartier-Harlin M.C., Dachsel J.C., Vilariño-Güell C., Lincoln S.J., Leprêtre F., Hulihan M.M., Kachergus J., Milnerwood A.J., Tapia L., Song M.S., Le Rhun E., Mutez E., Larvor L., Duflot A., Vanbesien-Mailliot C., Kreisler A., Ross O.A., Nishioka K., Soto-Ortolaza A.I., Cobb S.A., Melrose H.L., Behrouz B., Keeling B.H., Bacon J.A., Hentati E., Williams L., Yanagiya A., Sonenberg N., Lockhart P.J., Zubair A.C., Uitti R.J., Aasly J.O., Krygowska-Wajs A., Opala G., Wszolek Z.K., Frigerio R., Maraganore D.M., Gosal D., Lynch T., Hutchinson M., Bentivoglio A.R., Valente E.M., Nichols W.C., Pankratz N., Foroud T., Gibson R.A., Hentati F., Dickson D.W., Destée A., Farrer M.J. Translation initiator EIF4G1 mutations in familial Parkinson Disease. American Journal of Human Genetics. 2011;89:398–406. doi: 10.1016/j.ajhg.2011.08.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Guerreiro R.J., Washecka N., Hardy J., Singleton A. A thorough assessment of benign genetic variability in GRN and MAPT. Human Mutation. 2010;31:E1126–E1140. doi: 10.1002/humu.21152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P., Holton J.L., Healy D.G., Gilks W.P., Sweeney M.G., Ganguly M., Gibbons V., Gandhi S., Vaughan J., Eunson L.H., Katzenschlager R., Gayton J., Lennox G., Revesz T., Nicholl D., Bhatia K.P., Quinn N., Brooks D., Lees A.J., Davis M.B., Piccini P., Singleton A.B., Wood N.W. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain. 2005;128:2786–2796. doi: 10.1093/brain/awh667. [DOI] [PubMed] [Google Scholar]
  • 6.Ramensky V., Bork P., Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Research. 2002;30:3894–3900. doi: 10.1093/nar/gkf493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sheerin U.M., Charlesworth G., Bras J., Guerreiro R., Bhatia K., Foltynie T., Limousin P., Silveira-Moriyama L., Lees A., Wood N. Screening for VPS35 mutations in Parkinson's disease. Neurobiology of Aging. 2011:838.e1–838.e5. doi: 10.1016/j.neurobiolaging.2011.10.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Wang K., Li M., Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Research. 2010;38:e164. doi: 10.1093/nar/gkq603. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES